# Open-Source-in-New-Drug-Applications-NDAs-FDA
List of Open-Source in New Drug Applications NDAs FDA. Compiled for reserarch for conference talk. Feel free to send me more if I missed any. R at top and python is below. Oldest date for R is 2007.

# FDA references:
## R

## New for 2024 Analysis
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217188Orig1s000IntegratedR.pdf
2023
Pfizer, Inc.
"Source: adex.xpt and adsl.xpt; Software: R"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/050708Orig1s053;%20050709Orig1s045;%20210115Orig1s005.pdf
2021
Astellas Pharma US, Inc.
"FDA Response to Question 3c: We agree with the program submission using R markdown."

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761289Orig1s000MultidisciplineR.pdf
2022
AstraZeneca AB (Sweden)
"Source:az‐durvalumab‐pk‐model‐himalaya‐V1.0.Rmd"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/212608Orig1s006.pdf
2021
Blueprint Medicines Corporation
"“Population_PK_Review_Template_NDA212608” ".rmd and .docx files" "R markdown code and .docx output for
analyzing popPK dataset, popPK model, E-R safety dataset, and E-R efficacy dataset; code for Table 3, Table 6, Table 7, Table 12, Figure 5, Figure 6, Figure 7, Figure 8, Figure 31, and Figure 32."

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217369Orig2s000IntegratedR.pdf
2023
Sage Therapeutics
"Source: Study PPD-301 adae.xpt; Software: R"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761286Orig1s000IntegratedR.pdf
2023
UCB, Inc
"Source: adex.xpt and adsl.xpt; Software: R and MG0003 CSR Table 6.2.2"
"Primary analysis and plotting were performed in R 4.1.2."

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/202293Orig1s026.pdf
2023
AstraZeneca Pharmaceuticals LP
"Source: Reviewer’s analysis [adsl, adex]; Software: R"
"Source: Reviewer’s analysis [adsl, adae, adce, adtte]; Software: R"
"The statistical software R was used for safety analyses."

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf
2021
Bayer Healthcare Pharmaceuticals
"Source: adsl.xpt; Software: R"
"Source: adae.xpt; Software: Python"

https://www.fda.gov/media/168215/download
2023
Intercept Pharmaceuticals
*FDA Briefing Document for NDA 212833
"Source: Clinical data Scientist’s analysis of adae.xpt; Software: R (Ver 4.1.0)"

https://www.fda.gov/media/164666/download
2023
Cidara Therapeutics, Inc.
*FDA Briefing Document for NDA #217417
"Source: adae.xpt; software: R"

https://www.fda.gov/media/172242/download
2023
Intarcia Therapeutics, Inc.
*FDA Briefing Document for NDA #209053
"Source: CDER Review staff. Software: R v. 4.2 (IVC_plots.R);"
"Source: CDER Review staff. Analysis: R v. 4.3, survival package (Therneau and Grambsch 2000; Therneau 2023)."

https://www.fda.gov/media/165980/download
2023
Merck Sharp & Dohme Corp.
*Statistical Review - Vaccine
"I have independently verified the results related to the non-stratified analysis using BinomDiffCI function of DescTools package of the R software. I verified the stratified MN confidence interval using the scoreci function of the ratesci package in R. The summary of results is provided in Table 8"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209279Orig1s000MedR.pdf
Actelion
2017
"Source: Efficacy.Rmd."
"R code for all analyses and graphs."

## 2023 Analysis
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000StatR.pdf
2015
Actelion Pharmaceiticals

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000StatR.pdf
2013
Vanda Pharmaceuticals

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755orig1s000clinpharmr.pdf
2014
Novartis

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000StatR.pdf
2011
Astellas Pharma

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207988Orig1s000StatR.pdf
2014
Ardea Biosciences

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806orig1s000clinpharmr.pdf
2013
GlaxoSmithKline
“The statistical software R (www.r-project.org) and S-plus (Tibco, Palo Alto, CA) were used to generate all plots.“

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208573Orig1s000ClinPharmR.pdf
2015
AbbVie
"The statistical software R (version 3.05) and SAS (version 9.3) was used for statistical and
graphical"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf
2021
Supernus Pharmaceuticals
“Source: adds.xpt; Software, R. Table created by the Clinical Data Scientist.”

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203188Orig1s000StatR.pdf
2012
Vertex

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022129s000_StatR.pdf
2007
Summer’s Laboratories

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202022Orig1s000ClinPharmR.pdf
2011
Diagnosticgraphs, model comparison, and statistical analysis were performed in R
Tibotec

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209241oirg1s000clinpharmr.pdf
2016
Neurocrine Biosciences, Inc.
"The statistical software R (version 3.3.1) were utilized for dataset compilation, analyses and
generation of plots."

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213217Orig1s000MultidisciplineR.pdf
2020
BeiGene
"The statistical software R was utilized to generate review plots and summarize potential confounders by exposure group"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761044Orig1s003.pdf
2019
JNJ
"The statistical software R was utilized to generate the summary of potential confounders by exposure group."

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214103Orig1s000IntegratedR.pdf
2020
Alnylam Pharmaceuticals
Source: adds.xpt and Clinical Study Report; Software: R.

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761210Orig1s000MultidisciplineR.pdf
2020
Janssen Biotech
"outputs were performed using statistical software R (version 3.4.1 or later)"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf
2021
Cara Therapeutics, Inc.
"outputs were performed using statistical software R (version 3.6.2 or later)"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf
2022
Idorsia
"Source: adds.xpt and Clinical Study Report; Software: R,"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209296Orig1s000ClinPharmR.pdf
2017
Heron Therapeutics
"AUC0-inf was calculated using R package (“PK”) based on the last four plasma concentrations"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf
2020
Acacia Pharma Ltd
"The simulations and all subsequent calculations were performed using R (version 3.2.3 (2015- 11-30), The R Foundation for Statistical Computing, Platform: x86 64-pc-linux-gnu (64-bit)) and R-Studio (version 1.1.442 2009-2018 RStudio, Inc.)"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761178Orig1s000ClinPharm_Redacted.pdf
2020
Biogen, Inc.
"Non-linear mixed effects software NONMEM (version 7.3) and R Studio (version 1.2.5033) were used for dataset compilation, analyses and generation of plots"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761069Orig1s000ClinPharmR.pdf
2016
Astrazeneca
"All data processing and analyses were performed using R version 3.2.2 under R studio"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/Seife%20Production_2017_09_29%20Part%202_Redacted.pdf
2016
Serepta
"All analyses were done using SAS® (Version 9.3) and R Studio (Version 0.97.551)"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210795Orig1s000MultidisciplineR.pdf
GSK
2018
Page 210

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203093Orig1s000ClinPharmR.pdf
2012
Gilead Sciences
"Rstudio/R 2.14.0 were used for data manipulation and analysis"

## Python

https://www.fda.gov/media/168215/download
2023
*FDA Briefing Document NDA# 212833
Intercept Pharmaceuticals
"Source: FDA Review staff analysis using Applicant-submitted data adsl.xpt, adlbce.xpt, adlbhb.xpt, adcm.xpt, adexsum.xpt in
Python (Ver. 3)"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214410Orig1s000,%20210854Orig1s004,%20s010IntegratedR.pdf
2020
Genentech, Inc.
"Source: adae.xpt; Software: Python"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761194Orig1s000IntegratedR.pdf
2021
Genzyme Corporation
"Source: adsl.xpt; Software: Python"

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215498Orig1s000IntegratedR.pdf
2021
Albireo AB
"Source: Generated by CDS; adae.xpt; Software: Python;"

## Interesting

https://cran.r-project.org/web/packages/adaptIVPT/index.html
2024-01-26
Package provides procedures based on parallel replicate design and balanced data, according to the U.S. Food and Drug Administration's "Draft Guidance on Acyclovir"
https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acyclovir_topical%20cream_RLD%2021478_RV12-16.pdf
Maintained by FDA

https://www.fda.gov/media/172331/download
2023
FDA Introductory Remarks Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting September 21, 2023 ITCA 650 (exenatide in DUROS)
2023
"Source: CDER Review staff; software: R v. 4.2; Data: adsl.xpt (SDN0000) and subject listings from other CVOTs"

https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-kerendia
2021
Bayer Healthcare Pharmaceuticals Inc.
"Source: adsl.xpt and adae.xpt; Software: R"

https://covid19crc.org/wp-content/uploads/2020/09/mRNA-1273-P301-Protocol-2020.pdf
2020
Moderna
"Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older
The sample size is calculated using R package gsDesign (Anderson 2020)"

https://www.accessdata.fda.gov/CDRH510K/K102973.pdf
2011
References research done in R 90(2):203-208, 2011
"The assignments were generated by the project statistician, using the “sample” function of R statistical software (Version 2.7.1, The R Foundation for Statistical Computing, 2008)."

https://www.cdc.gov/mmwr/volumes/72/wr/mm7220a3.htm
2023
JYNNEOS Vaccine
"Analyses were conducted using the survival package in R statistical software (version 4.2.2; The R Foundation)."
